ZD 1839 in Treating Patients With Stage IV or Recurrent Kidney Cancer
- Conditions
- Kidney Cancer
- Registration Number
- NCT00014183
- Lead Sponsor
- University of Maryland, Baltimore
- Brief Summary
RATIONALE: Biological therapies such as ZD 1839 may interfere with the growth of the tumor cells and slow the growth of kidney cancer.
PURPOSE: Phase II trial to study the effectiveness of ZD 1839 in treating patients who have recurrent or stage IV kidney cancer.
- Detailed Description
OBJECTIVES:
* Determine the response rate in patients with progressive stage IV or recurrent renal cell cancer treated with ZD 1839.
* Determine the median time to objective progression in these patients receiving this drug.
* Determine the toxic effects of this drug in this patient population.
* Determine if epidermal growth factor receptor expression in tumor tissue correlates with response and survival of these patients.
OUTLINE: This is a multicenter study.
Patients receive oral ZD 1839 daily. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Patients are followed every 8 weeks.
PROJECTED ACCRUAL: A total of 21-45 patients will be accrued for this study within 11-23 months.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (2)
Veterans Affairs Medical Center - Baltimore
🇺🇸Baltimore, Maryland, United States
Marlene & Stewart Greenebaum Cancer Center, University of Maryland
🇺🇸Baltimore, Maryland, United States